Cynata治疗学已完成了对65名病人进行第二阶段试验的登记,测试了对移植后严重疾病的干细胞疗法,结果将于2026年6月完成。 Cynata Therapeutics finished enrolling 65 patients in a Phase 2 trial testing a stem cell therapy for severe post-transplant disease, with results due in June 2026.

Cynata治疗学在其第二阶段的CYP-001试验中完成了病人的注册,CYP-001是一种干细胞疗法,来自诱导的多功能干细胞,针对的是在骨髓移植后患有高风险急性移植与宿主疾病(aGvHD)的成年人。 Cynata Therapeutics has completed patient enrollment in its Phase 2 trial of CYP-001, a stem cell therapy derived from induced pluripotent stem cells, for adults with high-risk acute graft versus host disease (aGvHD) following bone marrow transplants. 审判包括美国、欧洲和澳大利亚各地65名参加者,他们被随机指派接受标准类固醇加上CYP-001或类固醇加安慰剂。 The trial included 65 participants across the U.S., Europe, and Australia, randomly assigned to receive either standard steroids plus CYP-001 or steroids plus placebo. 预计到2026年6月将取得的成果将侧重于100天期间第28天的总体回复率。 Results, expected by June 2026, will focus on overall response rate at day 28 over a 100-day period. 前一阶段的数据显示,反应和存活率都很强,没有严重的安全问题。 Previous Phase 1 data showed strong response and survival rates with no serious safety issues. CYP-001已经收到美国林业发展局的孤儿药物指认。 CYP-001 has received Orphan Drug Designation from the U.S. FDA.